AgeX Therapeutics, Inc. – AMEX:AGE

Add to watchlist

Market closed

Open in 2 days

-5.43%

month

-35.41%

quarter

-38.57%

year

Market Cap	27.75M
Enterprise value	31.08M

P/E	-2.19
EV/Sales	914.25
EV/EBITDA	-4.40
Price/Sales	708.34
Price/Book	-1.39
PEG ratio	0.10
EPS	-14.06

Revenue	116K
EBITDA	-10.01M
Income	-20.96M
Revenue Q/Q	-50%
Revenue Y/Y	197.43%

Profit margin	-30770.59%
Oper. margin	-20514.71%
Gross margin	61.76%
EBIT margin	-20514.71%
EBITDA margin	-8636.21%

Get more financial ratios!

Every financial ratio you might need
10 years history
Forward ratios (Analysts estimates)

Personalize your watchlist with companies you want to keep track of and get notified in the smart feed every time fresh news arrives.

AgeX Therapeutics, Inc. (AMEX:AGE): Profit margin
Jun 2023	9K	-2.66M	-29655.56%
Sep 2023	46K	-5.40M	-11741.3%
Dec 2023	56K	-3.45M	-6171.43%
Mar 2024	5K	-9.43M	-188740%

AgeX Therapeutics, Inc. (AMEX:AGE): Debt to assets
Jun 2023	12277000	34.57M	281.61%
Sep 2023	12210000	39.85M	326.41%
Dec 2023	11965000	6.60M	55.22%
Mar 2024	10856000	15.16M	139.69%

AgeX Therapeutics, Inc. (AMEX:AGE): Cash Flow
Jun 2023	-2.01M	0	2M
Sep 2023	-1.86M	0	2M
Dec 2023	-2.05M	0	2M
Mar 2024	-1.57M	-14K	2.72M

AgeX Therapeutics alternative data

AgeX Therapeutics, Inc. (AMEX:AGE): Employee count
Aug 2023	5
Sep 2023	5
Oct 2023	5
Nov 2023	5
Dec 2023	5
Jan 2024	5
Feb 2024	5
Mar 2024	4
Apr 2024	4
May 2024	4
Jun 2024	4
Jul 2024	4

AgeX Therapeutics
Hedge Funds Holdings Q1 2023

9.04% -3.58%

of AGE is owned by hedge funds

20 -9

hedge funds hold AGE stock

3.43M -1.35M

shares is hold by hedge funds

AGE hedge funds holdings changes

AgeX Therapeutics
Insider Trading

AgeX Therapeutics, Inc. (AMEX:AGE): Insider trades (number of shares)
Period	Buy	Sel
Feb 2022	308565	0

Transaction	Date	Insider	Security	Shares	Price per share	Total value
Option	11 Mar 2023	WEST MICHAEL D officer: Chief Ex..	Restricted Stock Units	3,125	N/A	N/A
Option	11 Mar 2023	WEST MICHAEL D officer: Chief Ex..	Common Stock, $0.0001 par value	3,125	N/A	N/A
Option	11 Dec 2022	WEST MICHAEL D director, officer..	Restricted Stock Units	3,125	N/A	N/A
Option	11 Dec 2022	WEST MICHAEL D director, officer..	Common Stock, $0.0001 par value	3,125	N/A	N/A
Option	11 Sep 2022	WEST MICHAEL D director, officer..	Restricted Stock Units	3,125	N/A	N/A
Option	11 Sep 2022	WEST MICHAEL D director, officer..	Common Stock, $0.0001 par value	3,125	N/A	N/A
Option	11 Jun 2022	WEST MICHAEL D director, officer..	Restricted Stock Units	3,125	N/A	N/A
Option	11 Jun 2022	WEST MICHAEL D director, officer..	Common Stock, $0.0001 par value	3,125	N/A	N/A
Option	11 Mar 2022	WEST MICHAEL D director, officer..	Restricted Stock Units	3,125	N/A	N/A
Option	11 Mar 2022	WEST MICHAEL D director, officer..	Common Stock, $0.0001 par value	3,125	N/A	N/A

AGE insider trading transactions

Status	Patent	Filling date	Issue date
Application	Application METHODS FOR DETECTING AND MODULATING THE EMBRYONIC-FETAL TRANSITION IN MAMMALIAN SPECIES Filling date: 6 Dec 2021 Issue date: 26 May 2022	6 Dec 2021	26 May 2022
Application	Application COMPOSITIONS AND METHODS FOR INDUCED TISSUE REGENERATION IN MAMMALIAN SPECIES Filling date: 17 Feb 2021 Issue date: 14 Apr 2022	17 Feb 2021	14 Apr 2022
Application	Application METHODS FOR DETECTING AND MODULATING THE EMBRYONIC-FETAL TRANSITION IN MAMMALIAN SPECIES Filling date: 6 Dec 2021 Issue date: 24 Mar 2022	6 Dec 2021	24 Mar 2022
Application	Application METHODS FOR DETECTING AND MODULATING THE EMBRYONIC-FETAL TRANSITION IN MAMMALIAN SPECIES Filling date: 6 Dec 2021 Issue date: 24 Mar 2022	6 Dec 2021	24 Mar 2022
Application	Application THERAPEUTIC EXOSOMES AND METHOD OF PRODUCING THEM Filling date: 22 Jan 2021 Issue date: 4 Nov 2021	22 Jan 2021	4 Nov 2021
Application	Application IMPROVED METHODS FOR INDUCING TISSUE REGENERATION AND SENOLYSIS IN MAMMALIAN CELLS Filling date: 23 Apr 2019 Issue date: 17 Jun 2021	23 Apr 2019	17 Jun 2021
Grant	Grant Utility: Compositions and methods for induced tissue regeneration in mammalian species Filling date: 3 Jun 2014 Issue date: 30 Mar 2021	3 Jun 2014	30 Mar 2021
Application	Application HLA G-MODIFIED CELLS AND METHODS Filling date: 27 Mar 2020 Issue date: 1 Oct 2020	27 Mar 2020	1 Oct 2020
Application	Application INDUCED TISSUE REGENERATION USING EXTRACELLULAR VESICLES Filling date: 27 Mar 2020 Issue date: 1 Oct 2020	27 Mar 2020	1 Oct 2020
Application	Application COMPOSITIONS AND METHODS FOR DETECTING CARDIOTOXICITY Filling date: 7 Jan 2020 Issue date: 16 Jul 2020	7 Jan 2020	16 Jul 2020

AgeX Therapeutics
Executives

Insider	Age	Compensation
Dr. Michael D. West Ph.D. (1953) Founder, Pres, Chief Executive Officer & Director	72	$561,030
Dr. Nafees Naseer Malik M.D. (1977) Chief Operating Officer	48	$282,270
Ms. Eun-Jae Park CPA (1972) Chief Financial Officer	53	$277,350

AgeX Therapeutics
Latest News

Wednesday, 21 August 2024
08:00	DiagnaMed Expands with Drug and Clinical Research AI Platform	globenewswire.com
Monday, 20 May 2024
07:17	Bitcoin dominance surges as crypto markets show signs of consolidation	https://www.proactiveinvestors.com
Tuesday, 16 April 2024
12:55	QVC DEFINES A NEW AGE OF POSSIBILITY CHAMPIONING WOMEN 50 AND OVER TO LIVE THEIR BEST LIVES	prnewswire.com
Tuesday, 26 March 2024
17:04	Serina Therapeutics Announces Completion of Merger with AgeX Therapeutics	globenewswire.com
Friday, 22 March 2024
17:27	AgeX Therapeutics Reports Fourth Quarter and Annual 2023 Financial Results	globenewswire.com
Tuesday, 27 February 2024
15:19	AGEX THERAPEUTICS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Merger of AgeX Therapeutics, Inc. - AGE	businesswire.com
Wednesday, 30 August 2023
10:22	Serina Therapeutics merger promises to reboot ‘human longevity' firm AgeX	Proactive Investors
Friday, 13 August 2021
16:05	AgeX Therapeutics Reports Second Quarter 2021 Financial Results	Business Wire

Ideas & Opinions

Seeking Alpha 14 Apr 2021

AgeX Therapeutics: New LyGenesis Merger May Unlock Much-Needed Value

Frequently Asked Questions (FAQ)

When is AgeX Therapeutics's next earnings date?

Unfortunately, AgeX Therapeutics's (AGE) next earnings date is currently unknown.
Does AgeX Therapeutics pay dividends?

No, AgeX Therapeutics does not pay dividends.
How much money does AgeX Therapeutics make?

AgeX Therapeutics has a market capitalization of 27.75M and it's past years’ income statements indicate that its last revenue has increased compared to the previous period by 317.65% to 142K US dollars.
What is AgeX Therapeutics's stock symbol?

AgeX Therapeutics, Inc. is traded on the AMEX under the ticker symbol "AGE".
What is AgeX Therapeutics's primary industry?

Company operates in the Healthcare sector and Biotechnology industry.
How do i buy shares of AgeX Therapeutics?

Shares of AgeX Therapeutics can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Who are AgeX Therapeutics's key executives?
AgeX Therapeutics's management team includes the following people:
- Dr. Michael D. West Ph.D. Founder, Pres, Chief Executive Officer & Director(age: 72, pay: $561,030)
- Dr. Nafees Naseer Malik M.D. Chief Operating Officer(age: 48, pay: $282,270)
- Ms. Eun-Jae Park CPA Chief Financial Officer(age: 53, pay: $277,350)
Is AgeX Therapeutics founder-led company?

Yes, AgeX Therapeutics is a company led by its founder Dr. Michael D. West Ph.D..
How many employees does AgeX Therapeutics have?

As Jul 2024, AgeX Therapeutics employs 4 workers.
When AgeX Therapeutics went public?

AgeX Therapeutics, Inc. is publicly traded company for more then 6 years since IPO on 29 Nov 2018.
What is AgeX Therapeutics's official website?

The official website for AgeX Therapeutics is agexinc.com.
Where are AgeX Therapeutics's headquarters?

AgeX Therapeutics is headquartered at 1101 Marina Village Parkway, Alameda, CA.
How can i contact AgeX Therapeutics?

AgeX Therapeutics's mailing address is 1101 Marina Village Parkway, Alameda, CA and company can be reached via phone at +51 06718370.

AgeX Therapeutics, Inc.

agexinc.com

Exchange:

AMEX

Full time employees:

Industry:

Biotechnology

Sector:

Healthcare

AgeX Therapeutics, Inc., a biotechnology company, focuses on the development and commercialization of novel therapeutics targeting human aging and degenerative diseases in the United States. The company's lead cell-based therapeutic candidates in development include AGEX-BAT1, a cell therapy product candidate for the treatment of various age-related metabolic disorders, such as Type II adult-onset diabetes and obesity; and AGEX-VASC1, a cell-based therapy to restore vascular support in aged ischemic tissues, such as peripheral vascular disease and ischemic heart disease. Its lead drug-based therapeutic candidate for scarless wound repair in discovery is AGEX-iTR1547, a drug-based formulation; and lead biologic candidate for induced tissue regeneration is AGEX-iTR1550, a gene delivery technology. The company has a research collaboration with the University of California at Irvine to develop cellular therapies to treat neurological disorders and diseases. AgeX Therapeutics, Inc. was incorporated in 2017 and is based in Alameda, California.

+51 06718370

1101 Marina Village Parkway
Alameda, CA 94501

CIK: 0001708599
ISIN: US00848H1086
CUSIP: 00848H108